A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
Status:
Completed
Trial end date:
2019-05-16
Target enrollment:
Participant gender:
Summary
This is a multicenter, open label, Phase 1 dose-escalation study of BBI608 administered to
patients with relapsed, refractory hematologic malignancies, including multiple myeloma,
lymphoma, and others.
Phase:
Phase 1
Details
Lead Sponsor:
Boston Biomedical, Inc Sumitomo Dainippon Pharma Oncology, Inc